ANA MARIA
MUÑOZ PATIÑO
Profesora titular de universidade
Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas
Madrid, EspañaPublicacións en colaboración con investigadores/as de Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (21)
2024
-
Non-HLA angiotensin-type-1 receptor autoantibodies mediate the long-term loss of grafted neurons in Parkinson’s disease models
Stem Cell Research and Therapy, Vol. 15, Núm. 1
2023
-
Boolean analysis shows a high proportion of dopamine D2 receptors interacting with adenosine A2A receptors in striatal medium spiny neurons of mouse and non-human primate models of Parkinson's disease
Neurobiology of Disease, Vol. 188
-
Interactions between Angiotensin Type-1 Antagonists, Statins, and ROCK Inhibitors in a Rat Model of L-DOPA-Induced Dyskinesia
Antioxidants, Vol. 12, Núm. 7
-
The cannabinoid CB1 receptor interacts with the angiotensin AT2 receptor. Overexpression of AT2-CB1 receptor heteromers in the striatum of 6-hydroxydopamine hemilesioned rats
Experimental Neurology, Vol. 362
2022
2021
-
Diabetes, insulin and new therapeutic strategies for Parkinson's disease: Focus on glucagon-like peptide-1 receptor agonists
Frontiers in Neuroendocrinology, Vol. 62
-
Nadph-oxidase, rho-kinase and autophagy mediate the (Pro)renin-induced pro-inflammatory microglial response and enhancement of dopaminergic neuron death
Antioxidants, Vol. 10, Núm. 9
-
Novel Interactions Involving the Mas Receptor Show Potential of the Renin–Angiotensin system in the Regulation of Microglia Activation: Altered Expression in Parkinsonism and Dyskinesia
Neurotherapeutics, Vol. 18, Núm. 2, pp. 998-1016
2020
-
Angiotensin AT1and AT2receptor heteromer expression in the hemilesioned rat model of Parkinson's disease that increases with levodopa-induced dyskinesia
Journal of Neuroinflammation, Vol. 17, Núm. 1
-
Interactions Between the Serotonergic and Other Neurotransmitter Systems in the Basal Ganglia: Role in Parkinson’s Disease and Adverse Effects of L-DOPA
Frontiers in Neuroanatomy, Vol. 14
-
Rho kinase inhibitor fasudil reduces l-DOPA-induced dyskinesia in a rat model of Parkinson's disease
British Journal of Pharmacology, Vol. 177, Núm. 24, pp. 5622-5641
2018
-
Physical exercise improves aging-related changes in angiotensin, IGF-1, SIRT1, SIRT3, and VEGF in the substantia Nigra
Journals of Gerontology - Series A Biological Sciences and Medical Sciences, Vol. 73, Núm. 12, pp. 1594-1601
2017
-
BDNF over-expression induces striatal serotonin fiber sprouting and increases the susceptibility to L-DOPA-induced dyskinesia in 6-OHDA-lesioned rats
Experimental Neurology, Vol. 297, pp. 73-81
2016
-
Hints on the Lateralization of Dopamine Binding to D
1
Receptors in Rat Striatum
Molecular Neurobiology, Vol. 53, Núm. 8, pp. 5436-5445
-
Aging-related Increase in Rho Kinase Activity in the Nigral Region is Counteracted by Physical Exercise
Journals of Gerontology - Series A Biological Sciences and Medical Sciences, Vol. 71, Núm. 10, pp. 1254-1257
-
Effects of rho kinase inhibitors on grafts of dopaminergic cell precursors in a rat model of Parkinson’s disease
Stem Cells Translational Medicine, Vol. 5, Núm. 6, pp. 804-815
2015
-
Stronger Dopamine D1 Receptor-Mediated Neurotransmission in Dyskinesia
Molecular Neurobiology, Vol. 52, Núm. 3, pp. 1408-1420
2014
-
Angiotensin type 1 receptor blockage reduces l-dopa-induced dyskinesia in the 6-OHDA model of Parkinson's disease. Involvement of vascular endothelial growth factor and interleukin-1β
Experimental Neurology, Vol. 261, pp. 720-732
2010
-
Nigral and striatal regulation of angiotensin receptor expression by dopamine and angiotensin in rodents: Implications for progression of Parkinson's disease
European Journal of Neuroscience, Vol. 32, Núm. 10, pp. 1695-1706
2009
-
Brain oxidative stress and selective behaviour of aluminium in specific areas of rat brain: Potential effects in a 6-OHDA-induced model of Parkinson's disease
Journal of Neurochemistry, Vol. 109, Núm. 3, pp. 879-888